Clinical trial NCT04587128: Early-Line Anti-EGFR Therapy to Facilitate Retreatment for Select Patients With mCRC
Official title: Phase II Trial of Early-Line Anti-EGFR Therapy to Facilitate Retreatment for Select Patients With Metastatic Colorectal Cancer
Study type: INTERVENTIONAL
Overall status: RECRUITING
Phase: PHASE2
Conditions: Metastatic Colorectal Cancer
Lead sponsor: University of Wisconsin, Madison
Sponsor class: OTHER
Collaborators: name: Doris Duke Charitable Foundation
First posted: 2020-10-14
Enrollment: 71
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: NON_RANDOMIZED
Intervention model: PARALLEL
Intervention model description: The study is an open label phase 2 clinical trial with 3 independent study arms conducted through the University of Wisconsin Carbone Cancer Center
Primary purpose: TREATMENT

Brief summary: The study will use previously established doses of panitumumab or cetuximab in the metastatic setting for the treatment of unresectable colorectal cancer (CRC). It is designed to investigate an alternative treatment strategy to maximize the benefit to inhibition of epidermal growth factor receptor (EGFR) for a highly selected patient population. It will enroll 71 participants with left-sided, unresectable metastatic CRC. Participants will be on study up to 5 years.


Eligibility criteria: Inclusion Criteria:

* Written informed consent and HIPAA authorization for release of personal health information
* As determined by the enrolling physician or protocol designee, ability of the participant to understand and comply with study procedures for the entire length of the study
* Eastern Cooperative Oncology Group (ECOG) Performance Status of 0 to 2
* Have a diagnosis of histologically confirmed metastatic colorectal cancer with primary tumor located beyond the splenic flexure. Histologic confirmation of a colorectal primary tumor is acceptable if accompanied by radiographic evidence of metastatic disease.

  * For Cohort A: Participants must enroll for study treatment in the first or second-line metastatic setting. Participants may receive 1 month of standard chemotherapy in the metastatic setting and still be eligible to initiate protocol therapy in the first-line setting. Adjuvant or neoadjuvant therapy does not count as a line of therapy even if given in the setting of metastatic disease (oligometastatic), unless disease recurrence was noted within 6 months of completing the last dose of the adjuvant or neoadjuvant therapy.
  * For Cohort B: Participants must have had at least stable disease (per treating physician) on a prior EGFR inhibitor containing regimen and it must be at least 4 months since the prior anti-EGFR inhibitor treatment was completed. Participants previously enrolled in Cohort A can later enroll in Cohort B should the eligibility criteria be met.
  * For Cohort C: Subjects must have had prior FOLFOX +/- VEGF inhibitor with no prior use of irinotecan or anti-EGFRi. If patients had prior FOLFOX and were treated on cohort A (of this study) they can cross-over to cohort C if other eligibility criteria are met at the time of cross-over.
* Evaluable disease according to RECIST v1.1. Participants do not have to have measureable disease.
* Participants with prior brain metastasis may be considered if they have completed their treatment for brain metastasis at least 4 weeks prior to study registration, have been off of corticosteroids for ≥ 2 weeks, and are asymptomatic.
* Demonstrate adequate organ function; all screening labs to be obtained within 7 days prior to registration. Note minimum platelet requirement differs between Cohort A and B.

  * Absolute Neutrophil Count (ANC) ≥ 1,000 / mcL
  * Platelets ≥ 50,000 / mcL (Cohort A); ≥ 50,000 mcL (Cohort B receiving only EGFRi); ≥75,000 / mcL (cohort B receiving irinotecan and EGFRi; and cohort C)
  * Serum creatinine OR measured or calculated creatinine clearance (GFR can also be used in place of creatinine or CrCl) ≤ 2.0 X upper limit of normal (ULN) OR ≥ 60 mL/min for subject with creatinine levels \> 2.0 X institutional ULN
  * Bilirubin ≤ 1.5 × ULN OR direct bilirubin ≤ ULN for subjects with bilirubin levels \>1.5 x ULN
  * Aspartate aminotransferase (AST) and Alanine aminotransferase (ALT) ≤ 5 × ULN
  * Albumin ≥ 2.5 mg/dL
* Females of childbearing potential must have a negative serum pregnancy test within 7 days of registration and not be breastfeeding. Females are considered of child bearing potential unless they are surgically sterile (have undergone a hysterectomy, bilateral tubal ligation, or bilateral oophorectomy) or they are naturally postmenopausal for at least 12 consecutive months.
* Females of childbearing potential and males must be willing to abstain from heterosexual activity or to use 2 forms of effective methods of contraception from the time of informed consent until 120 days after treatment discontinuation. The two contraception methods can be comprised of two barrier methods, or a barrier method plus a hormonal method.
* Tumor must be mismatch repair (MMR) proficient as determined by microsatellite instability or immunohistochemistry for MMR proteins

  * Microsatellite instability (MSI) testing must be MSI-stable or MSI-low.
  * Or IHC for MMR proteins must demonstrate intact MMR proteins.
* Baseline (prior to any anti-EGFR treatment) tumor molecular profiling with no pathologic variants in KRAS or NRAS or BRAF V600 mutations. If additional molecular profiling is completed (tissue or blood based testing) after receiving treatment for colon cancer and variants in KRAS or NRAS are found, those patients will be considered eligible for this study. Patients with BRAF V600 mutations are not eligible.
* Participants must not have known additional malignancy that is requiring systemic treatment. Participants taking hormonal treatments for breast or prostate cancer are still eligible.
* No major surgery within prior 2 weeks of treatment initiation (4 weeks if will be receiving bevacizumab).
* Urine protein less than 100 mg/dL if planning to receive bevacizumab.
* Blood pressure \<160/90 if planning to receive bevacizumab.
* No history of allergic reactions attributed to compounds of similar chemical or biologic composition to panitumumab or cetuximab, including known severe hypersensitivity reactions to monoclonal antibodies. No history of allergic reactions to 5-Fluorouracil, irinotecan, leucovorin or bevacizumab if the participant will be receiving that agent in this study.
* Participants must have no metastatic cancer lesions greater than 3.5cm in diameter. Any number of metastatic lesions will be allowed.

Primary outcomes:
measure: Disease Control Rate (DCR) at 6 months for Cohorts A and B
timeFrame: 6 months
measure: Cohort C Progression Free Survival (PFS)
timeFrame: up to 4 years
Secondary outcomes:
measure: Cohort A and B Progression Free Survival (PFS)
timeFrame: up to 4 years
measure: Cohort A, B, and C Objective Response Rate (ORR)
timeFrame: up to 1 year
measure: Type and Severity of Toxicities
timeFrame: up to 1 year (adverse events collected to 30 days post treatment)
measure: Rate of Retreatment with EGFRi for Cohorts A and B
timeFrame: up to 4 years
measure: Cohort A, B, and C Overall Survival (OS)
timeFrame: up to 4 years
Other outcomes:
measure: Change in Participant Derived Organotypic Spheroid Response over baseline
timeFrame: baseline, post treatment (up to 1 year)
measure: Circulating Tumor DNA (ctDNA) at time of Progression
timeFrame: 1 month (cycle 1, day 1 of 28 cycle), 4 months (cycle 3, day 1 of 28 day cycle), up to 1 year (30 days post treatment)
Locations:
city: Madison
country: United States
facility: University of Wisconsin Carbone Cancer Center
state: Wisconsin
Study officials:
affiliation: University of Wisconsin, Madison
name: Dustin Deming, MD
role: PRINCIPAL_INVESTIGATOR
References: